Novartis’s shares may have been in a torpor lately, but should investors really be selling them for less than their market price?
The Swiss pharmaceutical company is joining the ranks of major companies trying to bat away efforts by Canadian investment company TRC Capital to sweep up shares for a real bargain. Novartis said it’s been [...]
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment